Why Wattle Health Australia Ltd shares have been smashed today

Bubs Australia Ltd (ASX: BUB) isn’t the only infant formula hopeful that has seen its shares sink lower during trade today.

The Wattle Health Australia Ltd (ASX: WHA) share price has tumbled 7% to $2.58 on Wednesday following the release of its half-year results.

Like Bubs, Wattle Health unfortunately delivered a result that offered little by way of justification for its sizeable market capitalisation.

For the six months ended December 31, Wattle Health achieved sales of $661,261, down 17.5% on the prior corresponding half.

On the bottom line things were even worse, with the company’s half-year loss widening to a massive $13.1 million. Though it is worth pointing out that $9.6 million of this loss was attributable to share based payments.

Wattle Health finished the period with negative operating cash flow of -$2.8 million, leaving it with a cash balance of $9.6 million. This cash balance won’t last that long unless there is a serious ramp up in sales growth over the next 12 months.

Which admittedly is something that could potentially occur. Like Bubs, Wattle Health has signed numerous distribution agreements with the hope of making in-roads into the lucrative China market.

In addition to this, it has also recently received its first orders from the Indian and Macau markets. Whether these orders will lead to something significant in the future, only time will tell, but the response to the announcements was very positive and played a role in taking its shares to an all-time high this month.

Which leads us onto its market capitalisation. With 125 million shares outstanding, Wattle Health currently has a market capitalisation of $322.5 million.

Given these results, I think that valuation is hard to justify. While Wattle Health could strike it rich if its products are a success in the China market, there is no evidence as of yet that this will be the case and I think investors are playing a risky game here.

I hope that Wattle Health does become the next A2 Milk Company Ltd (ASX: A2M), but until its sales demonstrate this as being a possibility, I think investors ought to watch on from the safety of the sidelines.

Instead, these fast-growing mid cap shares could be the ones to put your money on in 2018. I expect them to smash the market...

The Disruptors: 3 Revolutionary Aussie Companies to Back for 2018

We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.

That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Cochlear or REA Group.

We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of A2 Milk. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.